Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Mohammed A Alblawi"'
Autor:
Raniah S. Alotibi, Naif S. Sannan, Mariam AlEissa, Marwh G. Aldriwesh, Abeer Al Tuwaijri, Maaged A. Akiel, Mashael Almutairi, Alhanouf Alsamer, Nouf Altharawi, Ghadah Aljawfan, Badi Alotiabi, Mohammed A. AlBlawi, Ahmed Alfares
Publikováno v:
Frontiers in Pediatrics, Vol 11 (2023)
BackgroundNeurodevelopmental disorders are a group of conditions characterized by developmental delays leading to abnormal brain functions. The methods of diagnosis and treatment of these conditions are complicated, and their treatment involves a com
Externí odkaz:
https://doaj.org/article/d00ea30db7dd4a65928be8f0a12d717f
Autor:
Mohammed A. Babatin, Abdulkareem M. Albekairy, Waleed Al-Tamimi, Sara I Altraif, Abduljaleel Alalwan, Musthafa Chalikandy Peedikayil, Khalid Alswat, Ayman A. Abdo, Mohammed Alquaiz, Waleed Al-Hamoudi, Mohammed A Alblawi, Shazia Murtaza, Fayaz A Handoo, Ibrahim Altraif, Abdulrahman Aljumah, Véronique Loustaud-Ratti, Faisal M. Sanai, Abdullah S. Alghamdi, Pierre Marquett, Fahad Alsohaibani, Hamad I. Al-Ashgar, Hamdan S. Alghamdi
Publikováno v:
Journal of interferoncytokine research : the official journal of the International Society for Interferon and Cytokine Research. 37(11)
Optimal doses of Ribavirin (RBV) for hepatitis C virus (HCV) treatment are not known. To assess the safety and efficacy of PegIFNalfa-2a in combination with an adjusted (ADJ) RBV dose based on early pharmacokinetics versus a fixed standard (STD) dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4402db3a97f78f63c93429b53272659a
https://pubmed.ncbi.nlm.nih.gov/29135370
https://pubmed.ncbi.nlm.nih.gov/29135370